Wednesday - April 23, 2025

LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

R1 RCM to Present at Upcoming Investor Conferences

May 02, 2023 | Last Trade: US$14.31 0.00 0.00

MURRAY, Utah, May 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences:

  • The Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10 at 10:00am PT
  • The 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16 at 9:00am ET

A live audio webcast of the presentation will be available on the Investor Relations section of R1’s website at ir.r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contact:
R1 RCM Inc.
Investor Relations:
Atif Rahim
312.324.5476
investorrelations@r1rcm.com

Media Relations:
Allison+Partners for R1RCM
Amanda Critelli
R1PR@allisonpr.com

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page